Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The intestine is one of the first affected organs in Parkinson's disease (PD). PD subjects show abnormal staining for Escherichia coli and α-synuclein in the colon. METHODS: We recruited 52 PD patients and 36 healthy cohabitants. We measured serum markers and quantified the numbers of 19 fecal bacterial groups/genera/species by quantitative RT-PCR of 16S or 23S rRNA. Although the six most predominant bacterial groups/genera/species covered on average 71.3% of total intestinal bacteria, our analysis was not comprehensive compared to metagenome analysis or 16S rRNA amplicon sequencing. RESULTS: In PD, the number of Lactobacillus was higher, while the sum of analyzed bacteria, Clostridium coccoides group, and Bacteroides fragilis group were lower than controls. Additionally, the sum of putative hydrogen-producing bacteria was lower in PD. A linear regression model to predict disease durations demonstrated that C. coccoides group and Lactobacillus gasseri subgroup had the largest negative and positive coefficients, respectively. As a linear regression model to predict stool frequencies showed that these bacteria were not associated with constipation, changes in these bacteria were unlikely to represent worsening of constipation in the course of progression of PD. In PD, the serum lipopolysaccharide (LPS)-binding protein levels were lower than controls, while the levels of serum diamine oxidase, a marker for intestinal mucosal integrity, remained unchanged in PD. CONCLUSIONS: The permeability to LPS is likely to be increased without compromising the integrity of intestinal mucosa in PD. The increased intestinal permeability in PD may make the patients susceptible to intestinal dysbiosis. Conversely, intestinal dysbiosis may lead to the increased intestinal permeability. One or both of the two mechanisms may be operational in development and progression of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with most of the diseases, PD patients have a different microbiota composition compared to healthy controls or patients affected by other neurological disorders (174–176).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [174]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A clinical study revealed that the level of serum LPS-binding protein in patients with Parkinson's disease was lower than that in controls, indicating that increased intestinal permeability and increased invasion of Gram-negative bacteria leads to an increase in LPS in the circulatory system.148”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“serum from PD patients contains low levels of LPS binding protein [145,146], which are indicative of a chronic systemic exposure to LPS and gram negative endobacteria [147,148,149]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [145]
In the citing paper
“Reduced number of Prevotella may be associated with decreased mucin synthesis causing increased gut permeability [413].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Postmortem studies of non-PD subjects disclosed incidental α-synuclein-positive Lewy bodies in the gastrointestinal tract, the olfactory system, and the cardiac sympathetic system, which suggests that α-synuclein pathology in PD may start in these tissues [2].”
BackgroundDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
(2023) · doi:10.1126/science · Cited by 6,063
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 2×
“Direct evidence supporting the notion that intestinal microbiota determines a clinical phenotype has been recently reported in obesity [9].”
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472 · cited 1×
“PD is predicted to affect more than 10 million people worldwide by the year 2030 [1].”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 3×
“In contrast to Prevotella, the count of Lactobacillus was increased 22-fold in the previous report [10], and 6.”
BackgroundResultOccurrence, Classification, and Biological Function of Hydrogenases: An Overview
Vignais, P. M., & Billoud, B. (2007) · Chemical Reviews · doi:10.1021/cr050196r · Cited by 1,578 · cited 1×
“According to an extensive review of bacterial hydrogenases [25], B.”
BackgroundDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 1×
“Intestinal microbiota in PD was recently published [10, 11].”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · cited 4×
“In PD, intestinal permeability is increased and the hyperpermeability is correlated with increased intestinal staining for Escherichia coli; nitrotyrosine, a marker for protein oxidation; and α-synuclein [7].”
BackgroundResultInfluential
Cited by
Items 201–300 of 538
Kulcsarova, K., Bang, C., Berg, D., & Schaeffer, E. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-230206 · Cited by 40
“Several microbial shifts were in line with changes reported in human PD patients: increased Lactobacillus and Bifi-dobacterium [174–177]andincreased Clostridiaceae and reduced Lachnospiraceae and Prevotellaceae [175, 178, 179].”
ResultDigesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson’s disease
Anis, E., Xie, A., Brundin, L., & Brundin, P. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.11.005 · Cited by 41
Bai, F., You, L., Lei, H., & Li, X. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112444 · Cited by 43
“In recent years, several studies that focused on the link between GM and PD have been published and revealed that PD may well be associated with GM (Aho et al., 2019; Hasegawa et al., 2015; Hill-Burns et al., 2017; Pie-trucci et al., 2019).”
BackgroundGhassab, F. T., Mahmoudi, F. S., Tinjani, R. T., Meibodi, A. E., Zali, M. R., & Yadegar, A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122748 · Cited by 41
Papel de la microbiota intestinal en el desarrollo de diferentes enfermedades neurológicas
Castillo-Álvarez, F., & Marzo-Sola, M. E. (2022) · Neurología · doi:10.1016/j.nrl.2019.03.017 · Cited by 37
Role of the gut microbiota in the development of various neurological diseases
Castillo-Álvarez, F., & Marzo-Sola, M. E. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2019.03.026 · Cited by 46
Aghamohammad, S., Hafezi, A., & Rohani, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114816 · Cited by 48
Microbiome–gut–brain dysfunction in prodromal and symptomatic Lewy body diseases
Ryman, S., Vakhtin, A. A., Richardson, S. P., & Lin, H. C. (2023) · Journal of Neurology · doi:10.1007/s00415-022-11461-9 · Cited by 38
“Plasma and serum lipopolysaccharide-binding protein is reduced in PD [102–104].”
Emerging Role of Diet and Microbiota Interactions in Neuroinflammation
Janakiraman, M., & Krishnamoorthy, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02067 · Cited by 38
Ikeda, T., Aida, M., Yoshida, Y., Matsumoto, S., Tanaka, M., Nakayama, J., Nagao, Y., Nakata, R., Oki, E., Akahoshi, T., et al. (2020) · British journal of surgery · doi:10.1002/bjs.11654 · Cited by 41
Changes in Gastrointestinal Microbiome Composition in PD: A Pivotal Role of Covariates
Cosma-Grigorov, A., Meixner, H., Mrochen, A., Wirtz, S., Winkler, J., & Marxreiter, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01041 · Cited by 38
“Two studies used quantitative RTPCR (55, 56), one used metagenomic shotgun sequencing (44).”
MethodGut Microbiota and Immune System Dynamics in Parkinson’s and Alzheimer’s Diseases
Kuštrimović, N. Z., Balkhi, S., Bilato, G., & Mortara, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212164 · Cited by 45
“Several studies, including those by Keshavarzian et al. [129] in the USA, Li et al. [134] in China, Unger et al. [135] in Germany, and Hasegawa et al. [136] in Japan, reported a mild reduction in Prevotella abundance among PD patients.”
The neuromicrobiology of Parkinson’s disease: A unifying theory
Muñoz, M., Empadinhas, N., & Cardoso, S. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101396 · Cited by 39
“Several other studies also reported lower relative levels of Prevotella spp. in PD patients (Bedarf et al., 2017; Hasegawa et al., 2015; Lin et al., 2019; Scheperjans et al., 2015; Unger et al., 2016).”
Melis, M., Vascellari, S., Santoru, M. L., Oppo, V., Fabbri, M., Sarchioto, M., Murgia, D., Zibetti, M., Lopiano, L., Serra, A., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14644 · Cited by 37
Aktaş, B., Aslım, B., & Özdemir, D. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-65061-w · Cited by 40
Irritable bowel syndrome and Parkinson’s disease risk: register-based studies
Liu, B., Sjölander, A., Pedersen, N. L., Ludvigsson, J. F., Chen, H., Fang, F., & Wirdefeldt, K. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-020-00145-8 · Cited by 39
Gut Microbiota and Parkinson’s Disease: Implications for Faecal Microbiota Transplantation Therapy
Kang, Y., Kang, X., Zhang, H., Liu, Q., Yang, H., & Fan, W. (2021) · ASN NEURO · doi:10.1177/17590914211016217 · Cited by 39
“Human PD Lactobacillus ", Prevotella #, Clostridium coccoides #, Bacteroides fragilis, #, Hydrogen-producing bacteria # (Hasegawa et al., 2015)”
BackgroundResultBicknell, B. T., Liebert, A. D., McLachlan, C. S., & Kiat, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010049 · Cited by 39
Thangaleela, S., Sivamaruthi, B. S., Kesika, P., Bharathi, M., & Chaiyasut, C. (2022) · Microorganisms · doi:10.3390/microorganisms10081544 · Cited by 39
Oral and intestinal dysbiosis in Parkinson's disease
Berthouzoz, E., Lazarević, V., Zekeridou, A., Jiménez, M. C., Debove, I., Aybek, S., Schrenzel, J., Burkhard, P. R., & Fleury, V. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.010 · Cited by 40
Gut Microbiota and Aging: Traditional Chinese Medicine and Modern Medicine
Li, J., Li, D., Chen, Y., Chen, W., Xu, J., & Gao, L. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s414714 · Cited by 40
Deidda, G., & Biazzo, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.753915 · Cited by 41
Zhao, Y., Walker, D. I., Lill, C. M., Bloem, B. R., Darweesh, S. K. L., Pinto‐Pacheco, B., McNeil, B., Miller, G. W., Heath, A. K., Frissen, M., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02846-2 · Cited by 37
Relationship among Parkinson’s disease, constipation, microbes, and microbiological therapy
Yuan, X.-Y., Chen, Y., & Liu, Z. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i3.225 · Cited by 36
“A study on 52 patients with PD found that Enterobacteriaceae, abundant in the colon of patients with PD, negatively correlated with stool frequency[107].”
Bashir, Y., & Khan, A. U. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1030694 · Cited by 38
“Evidence from a number of research groups (Hasegawa et al., 2015; Keshavarzian et al., 2015; Sampson et al., 2016; Bedarf et al., 2017; Hill-Burns et al., 2017; Aho et al., 2019; Romano et al., 2021; Lubomski et al., 2022; Zhu et al., 2022) has emerged proposing a relationship between the gut microbiota and PD.”
BackgroundThe overlooked benefits of hydrogen-producing bacteria
Ichikawa, Y., Yamamoto, H., Hirano, S., Sato, B., Takefuji, Y., & Satoh, F. (2022) · Medical Gas Research · doi:10.4103/2045-9912.344977 · Cited by 35
Therapeutic Prospect of New Probiotics in Neurodegenerative Diseases
Bi, M., Liu, C., Wang, Y., & Liu, S. (2023) · Microorganisms · doi:10.3390/microorganisms11061527 · Cited by 38
Evidence for immune system alterations in peripheral biological fluids in Parkinson’s disease
Bartl, M., Xylaki, M., Bähr, M., Weber, S., Trenkwalder, C., & Mollenhauer, B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105744 · Cited by 33
van Vuuren, M. J., Nell, T. A., Carr, J. A., Kell, D. B., & Pretorius, E. (2020) · Biomolecules · doi:10.3390/biom11010030 · Cited by 40
“Interestingly, in a 2015 study, Hasegawa and coworkers also showed in 52 PD patients that LPS-binding protein levels were lower than in controls [103].”
BackgroundResultBhuiyan, P., Chen, Y., Karim, M., Dong, H., & Qian, Y. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.04.010 · Cited by 35
Microbes and Parkinson’s disease: from associations to mechanisms
Cannon, T., & Gruenheid, S. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2022.01.004 · Cited by 35
Gut brain axis: an insight into microbiota role in Parkinson’s disease
Moustafa, S. A., Abdou, S. M., Dawood, A. S., Azar, J., Elmorsy, E. M., Rizk, N., & Salama, M. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00808-2 · Cited by 37
Brain-gut-microbiota axis in Parkinson’s disease: A historical review and future perspective
Dong, S., Sun, M., He, C. H., & Cheng, H. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.015 · Cited by 34
Yang, H., Li, S., & Le, W. (2022) · Aging and Disease · doi:10.14336/ad.2022.01281 · Cited by 37
“Aho et al. [60] observed no evidence of increased gut permeability in PD patients evaluated by stool zonulin or plasma LBP.”
BackgroundBi, M., Feng, L., He, J., Liu, C., Wang, Y., Jiang, H., & Liu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101759 · Cited by 34
Role of the microbiota in inflammation-related related psychiatric disorders
Zhou, L., Wu, Q. J., Jiang, L., Rao, J., Gao, J., Zhao, F., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1613027 · Cited by 41
Can Microbiota Research Change Our Understanding of Neurodegenerative diseases?
Scheperjans, F. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2015-0012 · Cited by 34
Ilieva, N. M., Wallen, Z. D., & De Miranda, B. R. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116176 · Cited by 31
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
Palacios, N., Hannoun, A., Flahive, J., Ward, D., Goostrey, K., Deb, A., & Smith, K. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.574529 · Cited by 30
Hydrogen: An Endogenous Regulator of Liver Homeostasis
Zhang, Y., Xu, J., & Yang, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00877 · Cited by 32
“Moreover, the decreased endogenous H2 levels might also play essential roles in Parkinson’s disease, cerebral and myocardial I/R injuries, and chronic heart failure pathogenesis, while supplement of exogenous H2 may act as a possible therapy for these brain and heart diseases (Fu et al., 2009; Fujita et al., 2009; Shi…”
BackgroundStudy of the gut microbiome in Egyptian patients with Parkinson’s Disease
Mehanna, M., AbuRaya, S., Ahmed, S. M., Ashmawy, G. A. H. O., Ibrahim, A. E., & AbdelKhaliq, E. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02933-7 · Cited by 35
“Decreased diversity of gut microbiota has been associated with intestinal inflammation which can trigger mis-folding of α-synuclein in GI neurons [20].”
BackgroundSingh, Y., Trautwein, C., Dhariwal, A., Salker, M. S., Alauddin, M., Zizmare, L., Pelzl, L., Feger, M., Admard, J., Casadei, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72903-w · Cited by 35
Nielsen, S. D., Pearson, N. M., & Seidler, K. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147609 · Cited by 37
Update to the Treatment of Parkinson’s Disease Based on the Gut-Brain Axis Mechanism
Sun, X., Li, X., Wang, Z., & Xie, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.878239 · Cited by 31
“However, the levels of serum diamine oxidase, a marker for intestinal mucosal integrity, remained unchanged in PD (Hasegawa et al., 2015).”
BackgroundRecent research progress on metabolic syndrome and risk of Parkinson’s disease
Li, L., Liu, S., Zhuang, J.-L., Li, M.-M., Huang, Z., Chen, Y., Chen, X., Chen, C., Lin, S., & Ye, L. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0093 · Cited by 35
Riegelman, E., Xue, K. S., Wang, J.-S., & Tang, L. (2024) · Nutrients · doi:10.3390/nu16132041 · Cited by 36
Nutritional Intake and Gut Microbiome Composition Predict Parkinson’s Disease
Lubomski, M., Xu, X., Holmes, A. J., Müller, S., Yang, J. Y. H., Davis, R. L., & Sue, C. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.881872 · Cited by 29
“Interest in relationships between PD and the gut microbiome (GM) have increased since initial studies were published in 2015 (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015).”
BackgroundThe role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases
Tsafaras, G., & Baekelandt, V. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105806 · Cited by 28
“In addition, several studies have reported differences in the microbiome composition between healthy individuals and patients with PD (Barichella et al., 2019; Bedarf et al., 2017; Hasegawa et al., 2015; Hill-Burns et al., 2017; Hopfner et al., 2017; Keshavarzian et al., 2015; Li et al., 2017; Lin et al., 2018; Schepe…”
BackgroundChen, Z., Maqbool, J., Sajid, F., Hussain, G., & Sun, T. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104675 · Cited by 28
Buty and the beast: the complex role of butyrate in Parkinson’s disease
Elford, J. D., Becht, N. N., Garssen, J., Kraneveld, A. D., & Perez‐Pardo, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1388401 · Cited by 30
“Composition of the intestinal bacteria in individuals with PD has been assessed in several studies (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015; Unger et al., 2016; Bedarf et al., 2017; Hill-Burns et al., 2017; Hopfner et al., 2017; Li et al., 2017; 2019; Li et al.,…”
BackgroundDietary patterns affect Parkinson's disease via the microbiota-gut-brain axis
Chu, C., Yu, L., Chen, W., Tian, F., & Zhai, Q. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.07.004 · Cited by 29
Therapies for Parkinson’s disease and the gut microbiome: evidence for bidirectional connection
Hey, G. E., Nair, N., Klann, E. M., Gurrala, A., Safarpour, D., Mai, V., Ramirez‐Zamora, A., & Vedam‐Mai, V. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1151850 · Cited by 28
“There are now over 20 comprehensive studies that have investigated PD associated differences in gut microbiota composition (Hasegawa et al., 2015; Scheperjans et al., 2015; Unger et al., 2016; Li et al., 2017; HeintzBuschart et al., 2018; Lin et al., 2018).”
BackgroundThe Role of Bacteria-Derived Hydrogen Sulfide in Multiple Axes of Disease
Birg, A., & Lin, H. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073340 · Cited by 26
“Interestingly, PD patients were found to have increased permeability to LPS and intestinal permeability as can be seen in dysbiosis [115,116].”
Parkinson’s Disease: A Prionopathy?
Vascellari, S., & Manzin, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158022 · Cited by 37
Yeh, Y.-M., Lye, X.-Y., Lin, H.-Y., Wong, J.-Y., Wu, C.-C., Huang, C.-L., Tsai, Y.-C., & Wang, L. (2022) · Applied Animal Behaviour Science · doi:10.1016/j.applanim.2022.105569 · Cited by 27
Exploring the multifactorial aspects of Gut Microbiome in Parkinson’s Disease
Pavan, S., Prabhu, A., Gorthi, S. P., Das, B., Mutreja, A., Shetty, V., Ramamurthy, T., & Ballal, M. (2022) · Folia Microbiologica · doi:10.1007/s12223-022-00977-2 · Cited by 25
“suggest an increase in Lactobacillus gasseri subgroup can predict disease duration in PD (Hasegawa et al. 2015).”
BackgroundAktaş, B. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01319-7 · Cited by 28
“Moreover, intestinal permeability increased in people with PD (Hasegawa et al. 2015; Schwiertz et al. 2018).”
Parkinson's disease: Are gut microbes involved?
Omotosho, A. O., Tajudeen, Y. A., Oladipo, H. J., Yusuff, S. I., Abdulkadir, M., Muili, A. O., Egbewande, O. M., Yusuf, R. O., Faniran, Z. O., Afolabi, A. O., et al. (2023) · Brain and Behavior · doi:10.1002/brb3.3130 · Cited by 24
“Gut microbiota alterations in terms of number and diversity, based on the Unified Parkinson Disease Rating Scale (UPDRS), significantly impact motor and NMS of PD and serve as reliable biomarkers of the disease (Hasegawa et al., 2015).”
Vendrik, K. E. W., Chernova, V. O., Kuijper, E. J., Terveer, E. M., van Hilten, J. J., & Contarino, M. F. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-071766 · Cited by 29
A neuroscience perspective of the gut theory of Parkinson's disease
Smith, L. M., & Parr‐Brownlie, L. C. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13869 · Cited by 26
“In addition, changes in gut microflora have also been identified in Parkinson’s disease patients (Hasegawa et al., 2015; Keshavarizan et al., 2015; Scheperjans et al., 2015).”
BackgroundSong, S., Liu, J., Zhang, F., & Hong, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-72202-4 · Cited by 27
Drobny, A., Ngo, P. A., Neurath, M. F., Zunke, F., & López-Posadas, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655123 · Cited by 24
“PD pathogenesis is associated with “leaky gut” (Figure 1) and increased intestinal permeability (243), correlating with aSyn and LPS levels in the mucosa (190).”
BackgroundModulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond
Brown, E. G., & Goldman, S. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00942-2 · Cited by 28
Microbiome influences on neuro-immune interactions in neurodegenerative disease
Menees, K. B., Otero, B. A., & Tansey, M. G. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.07.006 · Cited by 27
α-synuclein overexpression and the microbiome shape the gut and brain metabolome in mice
Morais, L. H., Boktor, J. C., MahmoudianDehkordi, S., Kaddurah‐Daouk, R., & Mazmanian, S. K. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00816-w · Cited by 26
Bottoms up: the role of gut microbiota in brain health
Radisavljevic, N., Cirstea, M., & Brett Finlay, B. (2019) · Environmental Microbiology · doi:10.1111/1462-2920.14506 · Cited by 22
Patil, R. S., & Tupe, R. S. (2023) · Medicinal Research Reviews · doi:10.1002/med.21987 · Cited by 26
“Elevated levels of LPS 219 and declined LPS ‐ binding protein 194 in PD patients' blood are evidence of immune interplay with LPS, providing proof of PD ‐ related gut permeability impairments.”
BackgroundRedox-related gaseous mediators in the gastrointestinal tract
Naito, Y., Uchiyama, K., & Takagi, T. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.18-56 · Cited by 24
Jia, X., Chen, Q., Zhang, Y., & Asakawa, T. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1296713 · Cited by 22
Balakrishnan, R., Kang, S.-I., Lee, J. Y., Rho, Y., Kim, B.-K., & Choi, D. (2024) · Aging and Disease · doi:10.14336/ad.2024.1362 · Cited by 39
“In comparison to healthy individuals, PD patients were characterized by diminished levels of Bacteroides , Prevotella , Butyricicoccus , Pepto-streptococcus , and Lactobacillus spp., alongside enhanced levels of Enterobacter , Lactobacillus , and Proteus species [150].”
Wang, C., & Zheng, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.875349 · Cited by 24
“, 2020)), but also a decrease of total intestinal bacterial count compared to healthy controls (Hasegawa et al., 2015).”
BackgroundZhu, H., Zhang, H., Hou, B., Xu, B., Ji, L., & Wu, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9110560 · Cited by 29
“coli can disrupt the distribution of tight junction proteins and actin flaments in intestinal cells, thereby increasing intestinal permeability, disrupting intestinal barrier function [45, 46], and inducing neuroinfammation.”
BackgroundEmery, D. C., Davies, M., Cerajewska, T. L., Taylor, J., Hazell, M., Paterson, A. R., Allen, S. J., & West, N. X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1026260 · Cited by 27
Zhang, W., Dong, X., & Huang, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106787 · Cited by 25
Does gut brain axis has an impact on Parkinson’s disease (PD)?
Elangovan, A., Dahiya, B., Kirola, L., Iyer, M., Jeeth, P., Maharaj, S., Kumari, N., Lakhanpal, V., Michel, T. M., Rao, K. R. S. S., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102171 · Cited by 23
Scheperjans, F. (2017) · Movement Disorders · doi:10.1002/mds.27197 · Cited by 22
How leaky is the gut in Parkinson’s disease?
Derkinderen, P., Cossais, F., Kulcsárová, K., Škorvánek, M., Montaigne, L. S., Coron, E., Leclair‐Visonneau, L., Cerri, S., Pellegrini, C., & Rolli‐Derkinderen, M. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105796 · Cited by 24
“…had somewhat con fl icting results (Table 2): 5 studies reported lower LBP blood levels in cases with PD when compared to healthy controls, 67,69,72,73,75 whereas the 3 remaining studies found either no difference or even increased plasma LBP in PD. 62,74,76 There is no de fi nitive explanation for…”
Potential Applications of Blautia wexlerae in the Regulation of Host Metabolism
Rui, W., Li, X., Wang, L., Tang, X., & Yang, J. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10274-8 · Cited by 22
“Sun’s team and Hasegawa’s team found an increased abundance of Enterobacteriaceae and a decreasing abundance of Prevotella , Faecalibacterium , Blautia , and Bifidobacterium in the stools of PD patients [57, 58].”
Sadowski, K. A., Zając, W., Milanowski, Ł., Koziorowski, D., & Figura, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147741 · Cited by 24
Wang, S., Li, N., Zou, H.-X., & Wu, M. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.12.021 · Cited by 25
Choi, J. G., Huh, E., Kim, N., Kim, D., & Oh, M. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217194 · Cited by 24
Parkinson’s disease: Are gut microbes involved?
Bhattarai, Y., & Kashyap, P. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00058.2020 · Cited by 21
Mechanisms Underlying the Biological Effects of Molecular Hydrogen
Radyuk, S. N. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201211112846 · Cited by 21
Don’t forget the exogenous microbial transglutaminases: it is immunogenic and potentially pathogenic
Lerner, A., & Matthias, T. (2016) · AIMS Biophysics · doi:10.3934/biophy.2016.4.546 · Cited by 21
“In fact, mTg is a potential enhancer of tight junction permeability [5,6] and increased intestinal permeability is described in Parkinson’s disease [26], disrupted behavioral responses [27], stress, trauma and inflammation [28], brain dysfunction [29] and central autoimmune diseases like multiple…”
Delaney, S., & Hornig, M. (2018) · Current Environmental Health Reports · doi:10.1007/s40572-018-0186-z · Cited by 23
Forero-Rodríguez, J., Zimmermann, J., Taubenheim, J., Rodríguez, N. A., Caicedo, J. D., Best, L., Mendieta, C. V., López-Castiblanco, J. A., Gómez-Muñoz, L. A., Gonzalez-Santos, J., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12020325 · Cited by 26
“Additionally, changes in potassium could influence the regulation of K(+) channels and are important for cellular signaling in the basal ganglia; therefore, impairments in potassium could also have a relation with PD disease [103–105].”
BackgroundNeuron-specific regulation of superoxide dismutase amid pathogen-induced gut dysbiosis
Horspool, A. M., & Chang, H. C.-H. (2018) · Redox Biology · doi:10.1016/j.redox.2018.05.007 · Cited by 21
Lipopolysaccharide mouse models for Parkinson’s disease research: a critical appraisal
Bobrovskaya, L., & Deng, I. B. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.331866 · Cited by 25
“Therefore, decreased serum LBP in PD patients has been associated with chronic invasion of gram-negative bacteria (Forsyth et al., 2011; Hasegawa et al., 2015).”
Rusch, C. T., Beke, M., Tucciarone, L., Dixon, K., Nieves, C., Mai, V., Stiep, T., Tholanikunnel, T., Ramirez‐Zamora, A., Hess, C. W., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053336 · Cited by 20
Polyphenolic Compounds: Orchestrating Intestinal Microbiota Harmony during Aging
Pereira, Q. C., Fortunato, I. M., Oliveira, F. D. S., Alvarez, M. C., dos Santos, T. W., & Ribeiro, M. L. (2024) · Nutrients · doi:10.3390/nu16071066 · Cited by 19
Ahmed, H. S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04156-x · Cited by 22
Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease
Chen, S.-J., Chi, Y., Ho, C.-H., Yang, W., & Lin, C. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212574 · Cited by 24
“Several cross-sectional studies show reduced [13,15,16],butconflictingresultshave alsobeenreported[17].”
Hill, A. E., Wade‐Martins, R., & Burnet, P. W. J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708587 · Cited by 20
Lifestyle alters GUT-bacteria function: Linking immune response and host
Jazayeri, O., Daghighi, S. M., & Rezaee, F. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.009 · Cited by 21
The Role of The Gut Microbiome in Parkinson’s Disease
Gallop, A., Weagley, J. S., Paracha, S.-U.-R., & Grossberg, G. T. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211018268 · Cited by 20
“This includes lower levels of Prevotellaceae(18-21) and Lachnospiraceae(22-24) in individuals with PD, and higher levels of Verrucomicrobiaceae(20,22,24,25) Enterococcaceae and Lactobacillaceae.(20,24,26) Additionally, an association between Helicobacter pylori infection and PD has been reported, with a causative role…”
BackgroundInfluentialXiromerisiou, G., Marogianni, C., Androutsopoulou, A., Ntavaroukas, P., Mysiris, D. S., & Papoutsopoulou, S. (2023) · Biology · doi:10.3390/biology12010093 · Cited by 22
“Increased levels of LPS and decreased LPS-binding protein (LBP) in the blood and plasma of PD patients further support this hypothesis [46,47].”
ResultDefining Dysbiosis in Disorders of Movement and Motivation
Fields, C. T., Sampson, T. R., Bruce‐Keller, A. J., Kiraly, D. D., Hsiao, E. Y., & Vries, G. J. D. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1672-18.2018 · Cited by 21
“…or species within the Firmicutes phylum (Bedarf et al., 2017; Hill-Burns et al., 2017; Heintz-Buschart et al., 2018; Qian et al., 2018), whereas others report decreases in clusters of Clostridial species (Hasegawa et al., 2015; Scheperjans et al., 2015; Hill-Burns et al., 2017; Li et al., 2017).”
BackgroundCerroni, R., Pietrucci, D., Teofani, A., Chillemi, G., Liguori, C., Pierantozzi, M., Unida, V., Selmani, S., Mercuri, N. B., & Stefani, A. (2022) · Brain Sciences · doi:10.3390/brainsci12060739 · Cited by 18
Human gut microbiota and Parkinson's disease
Pant, A., Bisht, K. S., Aggarwal, S., & Maiti, T. K. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.08.004 · Cited by 18
The Role of an Altered Gut Microbiome in Parkinson’s Disease: A Narrative Review
Hashish, S. A., & Salama, M. (2023) · Applied Microbiology · doi:10.3390/applmicrobiol3020030 · Cited by 18
“suggested that an elevated level in the Lactobacillus gasseri subgroup may predict disease duration in PD [41].”
Background
Metadata
- Authors
- Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Yakult Central Institute (JP)
- Aichi University of Education (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-05
- Volume
- 10
- Issue
- 11
- Pages
- e0142164
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4634857
- OpenAlex
- W2097335121
- Cited by
- 523
- References
- 51
- Citations by year
- 2026: 28 · 2025: 38 · 2024: 51 · 2023: 79 · 2022: 70 · 2021: 80 · 2020: 57 · 2019: 41 · 2018: 51 · 2017: 22 · 2016: 6
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science (15K09350, 25870317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, lipopolysaccharide-binding protein, intestinal permeability, Lactobacillus, Clostridium coccoides, Bacteroides fragilis, hydrogen-producing bacteria, Lactobacillus gasseri, constipation, diamine oxidase, intestinal mucosal integrity, fecal microbiota, disease progression
- MeSH terms
- Lipopolysaccharide-Binding Protein, Acute-Phase Proteins, Aged, Bacteria, Carrier Proteins, Constipation, DNA, Bacterial, Feces, Female, Humans, Intestinal Mucosa, Male, Membrane Glycoproteins, Parkinson Disease, Permeability, RNA, Ribosomal, 16S, Case-Control Studies, Metagenome, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.